Mounjaro Side Effects: Complete List and Management Guide

Summary: Mounjaro causes nausea in up to 18 percent of patients, diarrhea in 17 percent, and decreased appetite in 11 percent. The diabetes-specific risks that matter more are hypoglycemia when stacked with insulin or a sulfonylurea, transient worsening of diabetic retinopathy when A1C drops fast, and acute kidney injury driven by dehydration from severe GI symptoms.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The most common Mounjaro side effects are gastrointestinal: nausea (up to 18 percent), diarrhea (up to 17 percent), decreased appetite (up to 11 percent), vomiting (up to 9 percent), indigestion (up to 8 percent), constipation (up to 7 percent), and stomach pain (up to 6 percent) ^[1]. Those numbers come from pooled SURPASS trial data in the FDA label. The diabetes-specific risks that get less screen time but matter more clinically are hypoglycemia when Mounjaro is combined with insulin or a sulfonylurea, transient worsening of diabetic retinopathy when blood sugar improves quickly, acute kidney injury driven by dehydration, and a boxed warning for thyroid C-cell tumors.

This page walks through every side effect documented in the SURPASS trials and the FDA label, organized by how often they happen and how serious they are when they do. It is written for people taking Mounjaro for type 2 diabetes. The same molecule is sold as Zepbound for weight loss, and the side effect profile is nearly identical, but a few things on this page (hypoglycemia interaction with diabetes drugs, retinopathy progression, CKD considerations) are sharper concerns in the diabetes population.

What Mounjaro is and why side effects happen

Mounjaro is the brand name for tirzepatide, a once-weekly subcutaneous injection approved by the FDA in May 2022 for type 2 diabetes. Tirzepatide is a dual agonist that binds both the GIP and GLP-1 receptors. The GLP-1 arm is shared with semaglutide (Ozempic) and liraglutide (Victoza). The GIP arm is unique among approved diabetes drugs.

Both receptors slow gastric emptying, increase satiety, and stimulate glucose-dependent insulin release. Those mechanisms are exactly what makes Mounjaro lower A1C by 1.8 to 2.4 percentage points in the SURPASS trials ^[2][3]. They also explain almost every side effect on this page. Slowed gastric emptying drives the nausea, vomiting, indigestion, and constipation. Improved insulin secretion drives the hypoglycemia risk when stacked with other glucose-lowering agents. Rapid A1C improvement drives transient retinopathy worsening. The drug works by changing how your gut, pancreas, and brain handle food, and those changes show up as symptoms in a predictable pattern.

Common gastrointestinal side effects

These are the symptoms reported by the largest share of patients in the SURPASS trials. Numbers cited are from the FDA label's pooled placebo-controlled data across SURPASS-1, SURPASS-3, and SURPASS-5 ^[1].

Nausea

Up to 18 percent of patients at the 15 mg dose. Most cases are mild to moderate. Nausea is worst in the first week after starting Mounjaro and after each dose increase, then settles within 2 to 4 weeks. Severe persistent nausea is the most common reason patients stop the drug.

Management that actually works:

• Eat smaller portions. Stop eating when you are 70 percent full, not when the plate is empty. Slowed gastric emptying means your stomach handles smaller meals better.
• Cut greasy and fried foods during the first week of any new dose. Fat slows gastric emptying further, which compounds the symptom.
• Ginger and peppermint are not folk medicine. Ginger has reproducible antiemetic data in clinical trials, and patients on GLP-1 drugs consistently report it helps.
• Stay hydrated. Sips of water all day beat large glasses at meals.
• If nausea is severe enough that you are skipping doses or losing weight you cannot afford to lose, your prescriber can write a short course of ondansetron or prochlorperazine.

Diarrhea

Up to 17 percent of patients. Loose or watery stools, most common in the first weeks of treatment and after dose increases. Usually improves over time.

What helps: stay hydrated, avoid spicy and fatty foods, skip sugar-free products containing sorbitol, mannitol, or xylitol (these draw water into the bowel and make Mounjaro diarrhea worse). Loperamide works for short-term control but talk to your prescriber before using it daily. If diarrhea is bloody, lasts more than a few days, or comes with fever, call your doctor. That is not a routine Mounjaro side effect.

People search for "why does Mounjaro cause diarrhea" expecting one answer. It is two: the GLP-1 receptor effect on gut motility (sometimes speeding the lower bowel even while slowing the stomach), plus rapid bile acid changes from altered fat digestion. The combination produces the classic GLP-1 diarrhea pattern.

Decreased appetite

Up to 11 percent of patients report it as a side effect, though appetite suppression is part of why Mounjaro works. You feel full faster and stay full longer. For type 2 diabetes patients, this drives weight loss alongside the glycemic improvement. The line between "wanted effect" and "side effect" is whether you are eating enough to meet nutrition needs. If you are skipping meals entirely or losing weight at a rate your doctor finds concerning, that crosses into side effect territory.

Vomiting

Up to 9 percent of patients. Usually accompanies nausea rather than appearing alone. Vomiting more than a few times in a day puts you at meaningful dehydration risk, which feeds into the acute kidney injury concern below. Two episodes is your prompt to call the prescriber and discuss whether the next scheduled dose should be held.

Indigestion, heartburn, and GERD

Up to 8 percent of patients report indigestion. Heartburn and acid reflux are reported on the same mechanism: slowed gastric emptying means stomach contents and acid sit longer than usual, which increases the chance of reflux into the esophagus. People who had occasional heartburn before Mounjaro often see it worsen. Management is the standard reflux toolkit: smaller meals, no lying down for 2 to 3 hours after eating, head of bed elevated for nighttime symptoms, and an OTC PPI like omeprazole for a short course if needed.

Mounjaro and GERD are not a contraindication. If symptoms are severe or you have a history of erosive esophagitis or Barrett's esophagus, talk to your doctor about whether the dose should escalate more slowly.

Constipation

Up to 7 percent of patients. The slowed-motility mechanism that helps with appetite also slows the lower bowel for some people. Increase fiber gradually (jumping fiber from 15 g to 35 g overnight causes its own GI mess), drink more water, and walk daily. OTC stool softeners like docusate or osmotic laxatives like polyethylene glycol are reasonable for short-term use.

Stomach pain

Up to 6 percent of patients. Mild cramping or discomfort is common and usually settles. Severe upper abdominal pain that radiates to your back, especially with vomiting, is a different category. That presentation is consistent with pancreatitis and is a call-911-or-go-to-the-ER situation, not a wait-and-see one.

Burping, sulfur burps, and flatulence

These are not in the FDA label's adverse event tables in a separate line, but they show up consistently in real-world reports and on the Mounjaro reviews aggregators. The mechanism is the same slowed gastric emptying plus altered fat digestion. Sulfur burps (also called "eggy burps" by enough patients that the phrase has its own search volume) are caused by hydrogen sulfide gas from food sitting too long in the stomach. They are usually self-limited and improve as the body adapts to each new dose.

Sulfur burps plus diarrhea together signal that your gut is having a particularly hard time clearing that meal. Smaller portions, less protein at once (high-protein meals make this worse), and avoiding red meat for a few days usually breaks the pattern.

Serious side effects with diabetes-specific implications

These are less common than the GI symptoms above, but the consequences are bigger and the diabetes context matters more.

Hypoglycemia when combined with insulin or a sulfonylurea

This is the most clinically important Mounjaro-specific concern for people with type 2 diabetes, and it is the one the FDA label flags first in the Warnings and Precautions section ^[1]. Mounjaro alone does not cause hypoglycemia. In SURPASS-1 (monotherapy versus placebo), the rate of hypoglycemia below 70 mg/dL in the Mounjaro arms was 6 to 7 percent, which was similar to placebo at 1 percent and clinically not different from background variability ^[2].

Stack Mounjaro on top of insulin or a sulfonylurea, and the math changes. From the SURPASS-5 trial (Mounjaro added to insulin glargine), hypoglycemia below 70 mg/dL occurred in 14 to 19 percent of patients ^[5]. In patients taking Mounjaro alongside a sulfonylurea, hypoglycemia occurs in 10 to 14 percent. Severe hypoglycemia (below 54 mg/dL) is rare but happens.

Symptoms of hypoglycemia: shakiness, sweating, blurry vision, dizziness, confusion, racing heartbeat, intense hunger. If your blood sugar reads at or below 70 mg/dL, take 15 grams of fast-acting carbohydrate (4 oz juice, 4 glucose tabs, a tablespoon of honey). Recheck in 15 minutes. If symptoms persist or your blood sugar is below 55 mg/dL, get emergency help.

Diabetic retinopathy worsening

This warning is specifically about people with type 2 diabetes and is one of the things that distinguishes the Mounjaro side effect profile from the Zepbound profile. When A1C drops quickly, as it does on Mounjaro for many patients, the retinal blood vessels in patients with pre-existing diabetic retinopathy can develop transient changes that worsen the retinopathy. This was observed across the SURPASS program. Symptoms include blurry vision, new floaters, dark spots in the visual field, or sudden vision changes.

If you have diabetic retinopathy already, your ophthalmologist should know you are starting Mounjaro. Many endocrinology and ophthalmology pairs coordinate a dilated eye exam at baseline and another 3 to 6 months after starting the drug if your A1C is dropping fast. If you notice vision changes during treatment, do not wait for your next routine appointment. Call your ophthalmologist.

The retinopathy worsening is generally transient and reflects rapid metabolic change rather than direct drug toxicity. The same phenomenon has been documented for decades with intensive insulin therapy and after bariatric surgery. The mechanism is not unique to GLP-1 drugs. The risk is real and the workup matters.

Acute kidney injury

Mounjaro itself is not nephrotoxic. The label warning about kidney injury is downstream of severe GI side effects: nausea, vomiting, and diarrhea cause dehydration, dehydration drops renal perfusion, and acute kidney injury follows. People with chronic kidney disease are at higher baseline risk, and AKI in a patient with stage 3 to 4 CKD takes longer to recover than in someone with normal baseline kidney function.

CKD considerations for Mounjaro:

• No dose adjustment is required based on kidney function. The drug is not renally cleared in a meaningful way.
• People with CKD should be monitored more aggressively for GI side effects and dehydration. The threshold to hold a dose if you are vomiting or have severe diarrhea is lower.
• Stay hydrated. The standard advice to drink fluids while sick is doubly important on Mounjaro because the GI side effects can outpace your fluid intake.

Symptoms of AKI: decreased urine output, swelling in legs or ankles, fatigue, confusion. Get medical care promptly if these appear, especially after several days of vomiting or diarrhea.

Pancreatitis

Reported in less than 1 percent of Mounjaro patients in clinical trials. The presentation is severe persistent upper abdominal pain, often radiating to the back, frequently with vomiting. People with a history of pancreatitis should generally not take Mounjaro. If pancreatitis is confirmed during treatment, the drug should be discontinued and not restarted.

This is a small absolute risk, but it is high stakes. Severe abdominal pain on Mounjaro is not a "see if it gets better in the morning" symptom. Go to the ER.

Gallbladder disease and gallstones

Up to 0.6 percent of patients in SURPASS trials developed gallbladder problems including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). Rapid weight loss is a known risk factor for gallstones independent of any specific drug, and Mounjaro produces enough weight loss to trigger that mechanism. Symptoms include severe upper-right abdominal pain, fever, clay-colored stools, or jaundice (yellowing of the skin or eyes). These warrant prompt medical evaluation.

Thyroid C-cell tumors (boxed warning)

The FDA boxed warning is based on rodent studies in which tirzepatide caused thyroid C-cell tumors. Whether this translates to humans is unknown. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1]. Patients should be told to watch for a neck mass, hoarseness, difficulty swallowing, or persistent shortness of breath.

Routine calcitonin monitoring is not recommended in the label. The FDA's position is that the rodent finding warrants the warning but the human relevance is uncertain. The same boxed warning exists on every approved GLP-1 receptor agonist.

Hypersensitivity and allergic reactions

Allergic reactions to Mounjaro are reported in roughly 3 percent of patients in pooled trial data, mostly mild (rash, itching). Severe reactions including angioedema and anaphylaxis are rare but documented. Severe allergic reaction symptoms (facial or throat swelling, difficulty breathing, hives spreading rapidly) require stopping the drug and emergency care. Mild local injection site reactions (redness, mild swelling, pain) are common and not the same thing as a systemic allergic reaction.

People search for "does Mounjaro contain sulfa" and "does Mounjaro have penicillin." It does not contain either. If you have a sulfa or penicillin allergy, that allergy is not a contraindication to Mounjaro.

Other reported side effects and frequently asked questions

These are symptoms patients ask about that did not appear at high rates in SURPASS trials but show up in post-marketing reports and patient discussions. Some are real Mounjaro effects, some are coincident, some are downstream of weight loss rather than the drug itself.

Fatigue and tiredness

Fatigue was reported in roughly 4 to 5 percent of patients in SURPASS trials. Usually mild and most common in the first few weeks. Likely related to reduced caloric intake during the early appetite suppression phase. Eat enough to meet your needs, hydrate, and the fatigue typically lifts. Persistent severe fatigue is worth a workup for other causes (anemia, thyroid, depression, sleep apnea), not just an assumption that it is the drug.

Injection site reactions

Mild redness, itching, or swelling at the injection site occurs in roughly 3 percent of patients. Usually self-limited. Rotate injection sites (abdomen, thigh, upper outer arm), let the pen warm to room temperature for a few minutes before injecting, and inject slowly. If you develop a persistent firm lump, a spreading red rash, or signs of infection (warmth, pus, fever), contact your doctor.

Hair loss

Hair loss was not reported as a side effect in Mounjaro's clinical trials. Patients on Mounjaro who lose weight rapidly sometimes experience telogen effluvium, a temporary shedding triggered by metabolic change. It is the same phenomenon documented after bariatric surgery, severe illness, or any major caloric deficit. Hair regrows over 3 to 6 months. Adequate protein intake (0.8 to 1.0 g per kg of body weight) and avoiding very low calorie diets while on Mounjaro reduce the risk.

Heart rate increase

Mounjaro raises heart rate by about 2 to 4 beats per minute on average. For most patients this is clinically irrelevant. People with pre-existing tachyarrhythmias or a history of palpitations should mention this to their cardiologist.

Mood changes, anxiety, depression

GLP-1 receptor agonists as a class have been investigated for possible psychiatric effects. The FDA reviewed a signal about suicidal ideation in 2024 and concluded the evidence did not support a causal link, though the agency continues to monitor. Real-world reports of anxiety, low mood, or "brain fog" on Mounjaro exist but are not consistently reproduced in trials. If you experience new or worsening depression, suicidal thoughts, or significant anxiety on Mounjaro, contact your prescriber.

Hair, skin, and other appearance complaints

Acne flares, eczema worsening, and rashes are reported anecdotally but are not in the trial adverse event tables at elevated rates compared to placebo. Most are coincident or driven by rapid weight loss. Yeast infections and urinary tract infections are not a known Mounjaro effect.

Hot flashes, night sweats

Not a documented Mounjaro side effect in trials. Reports of hot flashes during treatment are more often related to underlying hormonal status, hypoglycemia (which can present as sweating and flushing), or rapid metabolic change.

Bleeding, bruising, blood clots

Mounjaro does not have an established effect on bleeding or clotting. It does not interact with anticoagulants like warfarin or apixaban in a clinically meaningful way. Easy bruising should be evaluated independently.

Liver enzymes

Mild transient elevations in ALT or AST are reported in less than 2 percent of patients. Clinically significant liver injury is rare. People with fatty liver disease (NAFLD or MASH) usually see liver enzymes improve on Mounjaro because of weight loss and glycemic improvement, not worsen.

Cortisol, estrogen, testosterone, fertility

Mounjaro does not directly affect cortisol, estrogen, or testosterone levels. Weight loss can shift sex hormone binding globulin and free hormone levels indirectly, which is why some patients report changes in libido or menstrual cycles, but the drug itself is not endocrinologically active on those axes. Fertility is not directly affected, though weight loss can restore ovulation in women with PCOS. People who could become pregnant should use reliable contraception, because Mounjaro is not recommended during pregnancy and the drug can reduce the effectiveness of oral contraceptives by slowing gastric absorption. The FDA label specifically recommends a non-oral contraceptive method or adding a barrier method for four weeks after starting Mounjaro and four weeks after each dose escalation ^[1].

Sulfur burps, eggy burps, green stool, yellow urine

Sulfur burps (covered above) come from food sitting too long in the stomach. Green stool can occur when GI transit speeds up enough that bile pigment is not fully broken down before passing through; this is harmless on its own. Yellow urine is almost always either hydration status or B-vitamin supplementation, not a Mounjaro effect.

Withdrawal symptoms when stopping Mounjaro

Mounjaro does not have a chemical withdrawal syndrome. There are no physical dependence symptoms when you stop. What patients do experience after stopping is a return of appetite and a rebound in blood sugar. Most patients who stop Mounjaro regain a portion of the weight they lost within 6 to 12 months, and A1C drifts back toward pre-treatment levels. That is the underlying disease re-asserting itself, not withdrawal.

How side effect frequency changes with dose

The SURPASS trials tested 5 mg, 10 mg, and 15 mg maintenance doses. Side effect rates rise modestly with dose.

Rates are pulled from the FDA label's pooled placebo-controlled SURPASS-1, SURPASS-3, and SURPASS-5 data ^[1]. The takeaway: 15 mg is harder on the gut than 5 mg, but not dramatically so. Most patients who tolerate the titration well at 5 mg tolerate 10 mg and 15 mg with manageable additional symptoms. The patients who quit usually quit during titration, not after they reach maintenance.

When to call your doctor vs when to go to the ER

Mounjaro side effect FAQ

How long do Mounjaro side effects last?

Most GI side effects appear in the first 1 to 2 weeks of a new dose and improve over 2 to 4 weeks as the body adapts. Side effects that persist beyond a month at the same dose should prompt a call to your prescriber.

Does Mounjaro cause hair loss?

Hair loss was not reported in the SURPASS trials, but rapid weight loss can trigger telogen effluvium, a temporary shedding that resolves over 3 to 6 months. It is the weight loss, not the drug directly, and adequate protein intake helps.

Does Mounjaro cause fatigue?

Mild fatigue is reported in 4 to 5 percent of patients, usually in the first few weeks. Most often it reflects reduced caloric intake during early appetite suppression. Persistent severe fatigue should be worked up for other causes.

Does Mounjaro cause sulfur burps?

Sulfur burps happen on Mounjaro because slowed gastric emptying lets food sit longer in the stomach, producing hydrogen sulfide gas. Smaller portions, less red meat, and skipping high-protein meals when symptoms flare usually break the pattern.

Why does Mounjaro cause diarrhea?

Two mechanisms: the GLP-1 receptor effect on lower bowel motility, plus altered bile acid metabolism from changed fat digestion. Both peak in the first weeks of treatment and after dose increases.

Does Mounjaro cause hypoglycemia?

Not when used alone. Mounjaro monotherapy did not cause hypoglycemia at meaningful rates above placebo in SURPASS-1. Hypoglycemia rises sharply when Mounjaro is combined with insulin (14 to 19 percent) or a sulfonylurea (10 to 14 percent).

Does Mounjaro affect liver enzymes?

Mild transient ALT or AST elevations occur in less than 2 percent of patients. Most people with fatty liver disease see liver enzymes improve on Mounjaro due to weight loss and glycemic improvement.

Does Mounjaro cause pancreatitis?

Acute pancreatitis was reported in less than 1 percent of patients in trials. People with a history of pancreatitis should generally avoid Mounjaro. Severe upper abdominal pain radiating to the back is an emergency.

Can Mounjaro worsen diabetic retinopathy?

Yes, transiently, in people with pre-existing retinopathy whose A1C drops quickly. Get a dilated eye exam before starting and 3 to 6 months in if your A1C is improving fast. Vision changes during treatment warrant a same-week ophthalmology call.

Does Mounjaro cause heartburn or GERD?

Yes. Slowed gastric emptying means stomach contents and acid sit longer, increasing reflux risk. Standard reflux management works: smaller meals, no lying down for 2 to 3 hours after eating, OTC PPI for short courses.

Does Mounjaro cause acne, rashes, or itching?

Not at elevated rates in trials. Mild rashes are reported anecdotally. Severe itching, hives, or facial swelling are signs of allergic reaction and warrant stopping the drug and seeking care.

Does Mounjaro cause hot flashes or night sweats?

Not as a documented trial side effect. Sweating and flushing on Mounjaro are more commonly signs of hypoglycemia, especially in patients also taking insulin or a sulfonylurea. Check your blood sugar.

Does Mounjaro cause anxiety or depression?

Trials did not show elevated rates of mood disorders. FDA reviewed a 2024 signal about suicidal ideation in GLP-1 drugs and did not find a causal link. New or worsening mood symptoms during treatment should still be reported to your prescriber.

Does Mounjaro cause kidney damage?

Mounjaro is not directly nephrotoxic. Acute kidney injury during treatment is almost always dehydration-driven, secondary to severe vomiting or diarrhea. People with CKD need closer monitoring but do not need a dose adjustment.

Does Mounjaro cause hair loss specifically in women?

Same answer as for everyone. Hair shedding from rapid weight loss is real, temporary, and not unique to women. Adequate protein, iron sufficiency, and slower weight loss reduce the risk.

Does Mounjaro affect fertility or birth control?

Mounjaro does not directly affect fertility, though weight loss can restore ovulation in PCOS. The FDA label warns that Mounjaro can reduce the effectiveness of oral contraceptives by slowing gastric absorption. Use a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose escalation.

Are hiccups a Mounjaro side effect?

Not in the FDA label, but patients report them often. Likely related to slowed gastric emptying and gastric distension. Usually self-limited.

What happens if you accidentally take too much Mounjaro?

A double dose increases the severity of GI side effects. Mounjaro does not cause cardiovascular or neurological toxicity at supratherapeutic doses in case reports. Call Poison Control (1-800-222-1222 in the US) or your prescriber. Skip the next scheduled dose, return to the regular schedule the following week, and watch for severe nausea, vomiting, or hypoglycemia if you are also on insulin or a sulfonylurea.

Are Mounjaro withdrawal symptoms real?

There is no chemical withdrawal syndrome. After stopping, appetite returns and blood sugar drifts back toward pre-treatment levels over weeks to months. That is the underlying disease re-emerging, not withdrawal in the clinical sense.

What is the ICD-10 code for a Mounjaro adverse effect?

T50.B95A is the code for "Adverse effect of other antidiabetic and oral hypoglycemic drugs, initial encounter." Your provider will pick the specific code based on the symptom (T50.B95A plus the manifestation code).

Am I allergic to Mounjaro?

True hypersensitivity is rare. Symptoms include hives, facial or throat swelling, difficulty breathing, severe rash. Mild injection-site redness is not an allergy. Severe allergic symptoms require stopping the drug and emergency care.

Bottom line

Mounjaro is well-tolerated by most patients with type 2 diabetes, and the side effect profile is dominated by GI symptoms (nausea, diarrhea, decreased appetite, vomiting, indigestion, constipation, stomach pain) that are mild to moderate and improve over time. The serious risks that matter clinically are hypoglycemia when stacked with insulin or a sulfonylurea, transient diabetic retinopathy worsening with rapid A1C drop, acute kidney injury secondary to dehydration, pancreatitis, and the boxed warning for thyroid C-cell tumors. Most of these are manageable with appropriate monitoring and a careful titration schedule. The patients who do best are the ones who titrate slowly, hydrate aggressively, communicate with their prescriber early when symptoms worsen, and have insulin or sulfonylurea doses reviewed before they start.